· Research and development costs amounted to SEK 10.7 (10.5) m
· The loss after tax was SEK -14.9 (-13.9) m
· Earnings per share were SEK -0.08 (-0.14)
· The company had no net sales for the period
· The patient recruitment for the controlled phase II clinical study of ChronVac-C® in combination with standard-of-care is complete
· The development of ChronTech’s IVIN technology progresses according to plan
